How do I buy Biohaven Ltd. (BHVN) stock?

Buying Biohaven Ltd. (BHVN) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "BHVN", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy BHVN by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for BHVN on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Biohaven Ltd. from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Biohaven Ltd. (BHVN) pay dividends?

At the moment, Biohaven Ltd. (BHVN) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track BHVN's performance via the price chart in the Gotrade app.

Is buying BHVN on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy BHVN?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if BHVN is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Biohaven Ltd. (BHVN) Stock Price: Nov 11 Close $15.19

Latest news

Stocktwits

BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia

BHVNOctober 22, 2026

Stocktwits

BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia

BHVN

Investors Business Daily

Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting

NeutralBHVNOctober 22, 2026

Investors Business DailyNeutral

Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting

BHVN

Stocktwits

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights

BHVNOctober 10, 2026

Stocktwits

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights

BHVN

Stocktwits

BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?

BHVNSeptember 10, 2026

Stocktwits

BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?

BHVN

Investors Business Daily

BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout

BHVNAugust 26, 2026

Stocktwits

BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout

BHVN

Reuters

Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million

BHVNAugust 26, 2026

Reuters

Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million

BHVN

News tone: automated (AI) classification of the article's content, not a price prediction.

About Biohaven Ltd.

No description available.

SectorHealthcare

IndustryBiotechnology

Employees274

CEODr. Vladimir Coric M.D.

IPO DateSep 23, 2022

HeadquartersNew Haven, CT

Key Executives

Name	Title	Year Born
Dr. Vladimir Coric M.D.	Chairman & CEO	1971
Mr. Matthew Buten	Chief Financial Officer	1961
Ms. Kimberly Gentile	Senior Vice President of Clinical Operations	1966
Dr. Bruce D. Car D.V.M., DACVP, Ph.D.	Chief Innovation Officer	1962
Ms. Deb Young	Senior Director of Regulatory Affairs & Operations	—
Mr. George C. Clark CPA	VP & Chief Accounting Officer	1985
Mr. John McGill	Chief Technology Officer	—
Ms. Jennifer Porcelli	Vice President of Investor Relations	—
Mr. Warren Volles J.D.	General Counsel & Chief Legal Officer	—
Mr. Clifford Bechtold M.S.	President & GM of Biohaven Ireland Chief Compliance Officer	—

Fundamentals

Valuation

Price-to-book value-23.23

Profitability

Return on Equity-2272.00%

Return on Assets-140.00%

EBITDA$-532.30M

Trading

Average volume3,706,273

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 56.70
MACD 12/26/9: 0.57
EMA 9 of MACD: 0.52
MACD histogram: 0.05
SMA 50: $13.59; Price above SMA 50
EMA 50: $13.90; Price above EMA 50
SMA 200: $12.31; Price above SMA 200
EMA 200: $12.40; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

4 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Hold

50% Buy

50% Hold

0% Sell

Analyst price target

Low: $10.00
Average: $21.25
High: $32.00

Morgan Stanley

Terence Flynn

Buy

Target price

$21.00

HC Wainwright & Co.

Douglas Tsao

Hold

Target price

$10.00

RBC Capital

Leonid Timashev

Hold

Target price

$22.00

Canaccord Genuity

Sumant Kulkarni

Buy

Target price

$32.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-4.9	+25.1
2022	-4.5	-12.2	+4.0	-25.0	+53.7	+1.1	+0.5	+2.3	+0.9	-89.1	-5.6	-16.0
2023	+41.4	-18.8	-10.4	-5.9	+28.9	+15.4	-14.2	-6.9	+37.3	+10.1	+13.0	+27.2
2024	+6.1	+7.0	+10.4	-25.5	-12.6	+0.3	+11.4	+3.3	+30.9	+2.5	-9.6	-16.5
2025	+2.6	-1.4	-25.0	-2.1	-34.0	-10.0	+8.2	+4.6	-5.5	+16.1	-32.5	+21.1
2026	+9.1	-2.0	-28.4	-0.3	+14.3	+30.2	-14.3	+14.2	-15.2	+17.4	+0.2

Compare stocks

BHVN

Buy BHVN

Market cap

$2.29B

-

Price / Earnings ratio

-4.20

-

Price / Sales ratio

-

Dividend yield

0.00%

-

Average volume

3,706,273

-

Earnings per share

$-3.77

-

Biohaven Ltd. (BHVN) Stock

Key stats

Compare with BHVN

Recent news

BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia

BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia

Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting

Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights

BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?

BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia

BHVN Stock Eyes Biggest Single-Day Gain In 4 Years After FDA Approval For Vyglxia

Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting

Why Biohaven Catapulted 30%-Plus — And Why It Might Not Be Done Sprinting

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights

Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights

BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?

BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold?

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

Biohaven Plummets, A Boon For Rival Xenon, On A Surprise Seizure Setback

US FDA pauses new enrollment in Biohaven's epilepsy drug trials

US FDA pauses new enrollment in Biohaven's epilepsy drug trials

Why Biohaven Stock Was Rocking the Market This Week

Why Biohaven Stock Was Rocking the Market This Week

BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

BHVN Stock Soars 18% on $795M Out-Licensing Deal for Epilepsy Program

BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout

BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout

Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million

Biohaven licenses epilepsy drug to South Korea's SK Biopharmaceuticals for up to $795 million

About Biohaven Ltd.

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade